Redx Pharma Ltd. uses its Redox Switch technology to modify the pharmacophores of existing compounds in ways that flout conventional medicinal chemistry wisdom, aiming to generate best-in-class small molecules to treat cancer and infectious diseases. The company hopes to out-license its preclinical-stage assets to pharmas.

"Early target validation usually involves identifying a key pharmacophore in small molecules that is considered essential for binding the target" because minor structural changes to the pharmacophore will disrupt its interactions with key amino acids in the binding pocket, said CEO Neil Murray. "Thus, companies develop and patent compounds that modify the side chains but leave that pharmacophore untouched."